Developments in Immunotherapy for Urologic Cancers
16 Aug 202510:3010:45
Shu-Cheng WuTaiwanSpeakerDevelopments in Immunotherapy for Urologic CancersImmunotherapy has progressed rapidly in genitourinary (GU) oncology, especially in renal cell carcinoma and urothelial carcinoma, providing many patients with meaningful, quality-adjusted survival gains. Focusing on urothelial carcinoma, I will examine how physicians and patients engage in shared decision-making, and—drawing on real-world experience in Taiwan—outline the current applications and future prospects of immunotherapy for this malignancy.